Mabion S.A. (WSE:MAB)
9.64
-0.06 (-0.62%)
Jun 6, 2025, 5:00 PM CET
Mabion Company Description
Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland.
The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases.
It also offers clinical and commercial drug substance manufacturing of therapeutic proteins using mammalian and insect cell cultures, including biosimilars, monoclonals, vaccine antigens, and other recombinant proteins.
Its products include MabionCD20 and MabionHER2. Mabion S.A. was founded in 2007 and is headquartered in Konstantynów Łódzki, Poland.
Mabion S.A.
Country | Poland |
Founded | 2007 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 213 |
CEO | Krzysztof Kaczmarczyk |
Contact Details
Address: ul. gen. Mariana Langiewicza 60 Konstantynów Lódzki, 95-050 Poland | |
Phone | 48 42 207 7890 |
Website | mabion.eu |
Stock Details
Ticker Symbol | MAB |
Exchange | Warsaw Stock Exchange |
Fiscal Year | January - December |
Reporting Currency | PLN |
ISIN Number | PLMBION00016 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Krzysztof Kaczmarczyk | Chief Executive Officer and President of Management Board |
Grzegorz Grabowicz | Chief Financial Officer, Financial Director and Member of Management Board |
Dr. Slawomir Jaros EMBA, Eng., Ph.D. | Member of the Management Board and Scientific and Quality Director |
Adam Pietruszkiewicz | Member of Management Board and Business Development Director |
Julita Balcerek M.D. | Member of the Management Board, Operations Director and Chief Operating Officer |
Aneta Turek | Chief Accountant |
Pawel Pobiedzinski | Head of Logistics and Procurement |
Joanna Krolasik | Head of Microbiology Laboratory |